Figure: ACTIVATION OF B CELLS AND MACROPHAGES BY T HELPER CELLS
Click the image to enlarge

BIOMARKERS IN SARCOIDOSIS

Dear readers,

I have noticed that many patients, including myself, monitor ACE levels (angiotensin-converting enzyme). ACE is only one laboratory marker and, on its own, neither confirms nor rules out sarcoidosis.

After many years of health problems, and two years after I was diagnosed with sarcoidosis (D86.9), I decided to publish a brief overview of tests being studied for diagnosis and for assessing disease activity and prognosis. In August 2021, I was diagnosed with Löfgren syndrome; that was when I learned about sarcoidosis and began learning more about the disease.

What is sarcoidosis and where does it come from?

Sarcoidosis is an inflammatory disease of unknown cause, usually characterised by non-caseating granulomas—clusters of immune cells, especially macrophages and T lymphocytes. It probably develops through a complex interaction of hereditary factors, environmental exposures and the immune response; no single causative antigen has been confirmed.

Activated macrophages and T lymphocytes, along with cytokines that sustain inflammation, participate in granuloma formation. The number and type of involved cells and the course of disease differ among people; there is no reliable rule that there are four times more inflammatory macrophages.

It is my personal, as yet unconfirmed, hypothesis that disturbances in the maturation or function of T lymphocytes and their receptors (TCRs) may also contribute to disease development. This is not an established cause of sarcoidosis.

The causative antigen or group of antigens that triggers sarcoidosis has not yet been reliably identified. T-cell receptors (TCRs) and other immune mechanisms are being studied, but no single confirmed TCR or antigen is known that explains all cases. If we knew which TCR corresponds to the sarcoid antigen, identifying that antigen could enable a true biomarker and help find a treatment.

With current biomarkers, we can monitor disease activity by examining abnormalities and imbalances in B cells and T cells (lymphocytes), but they do not identify the cause of the disease that needs to be eliminated.

It is known that receptors of TH1 lymphocytes (which respond to intracellular pathogens), called CD40, recruit and activate macrophage receptors via the CD40L ligand, leading to phagocytosis and inflammation. New research shows much greater complexity in the activity and imbalance of B and T cells, leading to new biomarkers for more precise prognostic assessment. We know that immunohistochemical analysis of mediastinal lymph nodes shows a skewed CD4:CD8 T-cell ratio of 4:1.

New research is producing new conclusions. Most newly studied biomarkers in sarcoidosis have not been clinically validated and are not sufficiently specific or sensitive to be used alone for clinical decision-making. However, several sarcoidosis biomarkers play an important role in clinical management when used together with clinical data, including results from other biomarkers.

The most common biomarker used to assess sarcoidosis activity is ACE, but it is not reliable. Research shows that it is more accurate to use biomarkers of TH17 lymphocytes (which respond to extracellular bacteria and fungi), because they help predict disease prognosis. Liver-derived serum amyloid A (SAA) and other markers also correlate strongly with disease activity. If we understood this better, we might ask a doctor: “How prevalent are my TH17/TH17.1 cells together with elevated levels of TGF-β1, IFN-γ or IL-17A?”

Examples of findings from biomarker research:

TH17 cells that secrete TGF-β1 are associated with pulmonary fibrosis.

TH17.1 cells with a more TH1-like cytokine profile, i.e. IFN-γ expression, are associated with worse clinical outcomes, whereas those with a more classic TH17 cytokine profile, i.e. IL-17A expression, are associated with better outcomes.

Pulmonary hypertension: the neutrophil-to-lymphocyte ratio (NLR) was significantly higher in patients with sarcoidosis who developed pulmonary hypertension. (NLR = the ratio of neutrophils to lymphocytes in peripheral blood and the neutrophil count in BAL fluid.)

NLR and neutrophil count can be used as indicators of disease severity and prognosis in sarcoidosis.

Increased CXCL8 levels were detected in BAL fluid from patients with stage III sarcoidosis compared with CXCL8 levels in patients with Löfgren syndrome.

BIOMARKER LIST—HELP IN DETERMINING THE STAGE AND EXTENT OF SARCOIDOSIS


A. POSSIBLE REMISSION

1. Biomarker: Normalized expression levels of lymphocyte-specific tyrosine kinase (Lck), protein kinase C-theta (PKC-θ) and nuclear factor kappa B (NF-κB); normal secretion levels of IL-2 and IFN-γ
Cell: TH1 CD4+ cells
Sample: BALF

2. Biomarker: Reduced programmed cell death protein 1 (PD-1) on CD4+ cells
Cell: CD4+ cells
Sample: peripheral blood

3. Biomarker: Reduced TH17:T-regulatory cell (Treg) ratio
Cell: CD4+ cells
Sample: BALF and peripheral blood


B. Löfgren syndrome

1. Biomarker: CCR6+ CXCR3+ cells co-expressing T-bet and RORγT, which predominantly secrete IL-17A
Cell: TH17.1 CD4+ cells
Sample: BALF

2. Biomarker: High inducible co-stimulator (ICOS) expression on CD4+ CD25high FoxP3high cells
Cell: Treg
Sample: BALF

3. Biomarker: Lower levels of perforin and granzymes compared with non-Löfgren syndrome
Cell: CD8+ cells
Sample: BALF and peripheral blood


C. Chronic sarcoidosis (poorer outcomes)

1. Biomarker: Increased
Cell: CD163+
Sample: lymph nodes and lungs

2. Biomarker: Increased CCR6+ CXCR3+ cells that predominantly secrete IFN-γ
Cell: TH17.1 CD4+ cells
Sample: BALF

3. Biomarker: Increased CD4+ CD25high FoxP3high cells in peripheral blood
Cell: Treg
Sample: peripheral blood

4. Biomarker: Reduced CD25+ expression after stimulation
Cell: B cells
Sample: blood

5. Biomarker: Reduced NF-κB-p65 subunit in peripheral B cells
Cell: B cells
Sample: blood


D. Active/severe disease

1. Biomarker: Increased BAFF secretion
Cell: B cells
Sample: blood

2. Biomarker: High neutrophil-to-lymphocyte ratio and neutrophil count


E. Advanced radiological disease stage

1. Biomarker: Increased serum TARC and CCR4+ cells
Cell: TH2 CD4+
Sample: peripheral blood


F. Systemic organ involvement

1. Biomarker: CXCL9 levels
Cell: macrophages
Sample: peripheral blood

2. Biomarker: Reduced NF-κB-p65 subunit in CD4+ cells [5]; increased chitotriosidase
Cell: CD4+
Sample: BALF and peripheral blood

3. Biomarker: Increased chitotriosidase
Cell: macrophages
Sample: peripheral blood


G. Poorer pulmonary function tests

1. Biomarker: CXCL10 levels
Cell: macrophages
Sample: peripheral blood

2. Biomarker: Increased SAA levels
Cell: liver
Sample: peripheral blood


H. Fibrosis

1. Biomarker: Increased CCL18
Cell: M2 macrophages
Sample: BALF

2. Biomarker: Increased chitotriosidase
Cell: macrophages
Sample: peripheral blood

3. Biomarker: Increased CD152; reduced NF-κB-p65 subunit, CD3ζ and NF-ATc2 in CD4+ cells
Cell: CD4+
Sample: BALF and peripheral blood

4. Biomarker: Increased TGF-β secretion and STAT3 and PD-1 expression in TH17 cells
Cell: CD4+ TH17
Sample: peripheral blood


I. Response to corticosteroid therapy 

I.1. Requires intensified corticosteroid therapy High CD8 + 

1. Biomarker: High CD8+ CD27− cell count
Cell: CD8+ cells
Sample: peripheral blood

2. Biomarker: Increased SAA levels
Cell: liver
Sample: peripheral blood

3. Biomarker: Increased chitotriosidase
Cell: macrophages
Sample: peripheral blood


I.3. Relapses after corticosteroid therapy
1. Biomarker: Increased TH17:Treg ratio
Cell: CD4+
Sample: peripheral blood

I.2. May not benefit from corticosteroids
1. Biomarker: Low NF-κB
Cell: CD4+ cells
Sample: BALF and peripheral blood


You can use this table to compare your test results or better understand the stage and extent of your disease. I hope you find it useful.

Dino-Josip Ključarić
25 July 2023

Rating: 0 stars, 0 votes.